Aelix Therapeutics has presented phase 1/2a data on its therapeutic HIV vaccine candidate. Buoyed by the results, Gilead-partnered Aelix is preparing to raise cash and push into larger trials in pursuit of a functional cure for the disease.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,